Adalimumab-ryvk Kit
Product Images NDC 82009-158

37 FDA label images from Quallent Pharmaceuticals Health Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Adalimumab-ryvk (NDC 82009-158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Avt02 Pld Q 1)

Fig1 (Avt02 Pld Q 1)
A line graph showing the percentage of ACR20 responders over time in weeks, comparing the response between a 40 mg every other week dosing group and a placebo group. The graph indicates higher response rates in the 40 mg group across the observed period.*
FDA Label Image

Fig2 (Avt02 Pld Q 2)

Fig2 (Avt02 Pld Q 2)
A line graph showing the percentage of ASAS 20 response over 24 weeks comparing Adalimumab-ryvk (solid line) versus placebo (dashed line). The y-axis represents percentage response, reaching up to 70%, and the x-axis represents time in weeks from 0 to 24. The graph illustrates that Adalimumab-ryvk achieves a higher response rate than placebo throughout the time period.*
FDA Label Image

Fig3 (Avt02 Pld Q 3)

Fig3 (Avt02 Pld Q 3)
A line graph comparing treatment failure rates over 20 months between a placebo group and an Adalimumab group. The vertical axis represents treatment failure rate percentage, and the horizontal axis denotes time in months. The graph shows lower treatment failure in the Adalimumab group compared to placebo over the study duration.*
FDA Label Image

Fig3a (Avt02 Pld Q 4)

Fig3a (Avt02 Pld Q 4)
A line graph comparing treatment failure rates over 20 months for Adalimumab and placebo groups. The X-axis represents time in months and the Y-axis shows treatment failure percentage. Lines depict an increasing failure rate over time with distinct curves for placebo and Adalimumab treatments.*
FDA Label Image

1 (Avt02 Pld Q 5)

1 (Avt02 Pld Q 5)
Illustration diagram of an Adalimumab-ryvk 40 mg/0.4 mL subcutaneous injection kit showing labeled parts: clear cap covering the needle, orange needle sleeve, inspection window, and gray body grip area with a honeycomb pattern. The label includes storage instructions and the Quallent logo.*
FDA Label Image

Image (Avt02 Pld Q 6)

Image (Avt02 Pld Q 6)
An instructional diagram labeled Figure A showing a hand inserting a rectangular object, possibly a drug delivery device or component, into a machine or compartment with an arrow indicating the direction of insertion.*
FDA Label Image

Avt02-quallent-figure A-aw (Avt02 Pld Q 7)

Avt02-quallent-figure A-aw (Avt02 Pld Q 7)
Illustration of a clock showing a time interval from 15 to 30 minutes highlighted in red on the right half. The text "15 to 30 minutes" is centered on the clock face, with black hour marks at the 12, 3, 6, and 9 positions. Captioned as Figure B.*
FDA Label Image

Figbifuai (Avt02 Pld Q 8)

Figbifuai (Avt02 Pld Q 8)
An instructional diagram labeled Figure C showing a subcutaneous injection kit for Adalimumab-ryvk, including parts of a syringe and a cartridge. The diagram highlights where to find the expiration date and lot number on the device, indicated as EXP: YYYY/MM/DD and LOT no., with a note to keep refrigerated. The components include a white and orange assembly and a black part with text and textured grip.*
FDA Label Image

Image (Avt02 Pld Q 9)

Image (Avt02 Pld Q 9)
An instructional diagram labeled Figure D featuring components of a subcutaneous injection kit for Adalimumab-ryvk. The image includes a prefilled syringe labeled with drug information, an alcohol swab packet, a cotton ball, and a red sharps disposal container with a yellow lid.*
FDA Label Image

Image (Avt02 Pld Q 10)

Image (Avt02 Pld Q 10)
An instructional illustration labeled "Figure E" showing a person rinsing their hands under running water, with water and soap bubbles visible. This suggests a step in hand hygiene preparation.*
FDA Label Image

Avt02-quallent-figure E Aw (Avt02 Pld Q 11)

Avt02-quallent-figure E Aw (Avt02 Pld Q 11)
An illustration showing a front view of a human torso with highlighted injection sites for subcutaneous administration. Areas marked in orange include the abdomen around the navel and the front of both thighs. This diagram is related to the subcutaneous route of administration for Adalimumab-ryvk kit.*
FDA Label Image

Figfifuai (Avt02 Pld Q 12)

Figfifuai (Avt02 Pld Q 12)
An instructional illustration labeled Figure G showing a hand wiping a circular area on the skin with a cotton pad or swab, accompanied by circular arrows indicating a circular motion likely for cleansing the injection site.*
FDA Label Image

Figgifuai (Avt02 Pld Q 13)

Figgifuai (Avt02 Pld Q 13)
An instructional illustration showing the Adalimumab-ryvk injection pen with a close-up inset highlighting the window indicator on the device. The image includes label text of the product name and strength: 40 mg/0.4 mL, and the Quallent Pharmaceuticals logo is visible.*
FDA Label Image

Image (Avt02 Pld Q 14)

Image (Avt02 Pld Q 14)
An illustrated instructional diagram showing a hand holding an Adalimumab-ryvk subcutaneous kit component, with a focus on applying or positioning a small square adhesive patch or pad below it. This figure is labeled as Figure I and appears to demonstrate a step in the preparation or administration process using the kit.*
FDA Label Image

Image (Avt02 Pld Q 15)

Image (Avt02 Pld Q 15)
An instructional illustration showing a hand holding an Adalimumab-ryvk injection device at a 90-degree angle to the skin on another hand, demonstrating proper subcutaneous injection technique for the Adalimumab-ryvk 0.7 mL/mL kit by Quallent Pharmaceuticals Health LLC.*
FDA Label Image

Image (Avt02 Pld Q 16)

Image (Avt02 Pld Q 16)
Illustration showing the use of an Adalimumab-ryvk subcutaneous injection kit. It depicts a hand pressing the injection device onto the skin with the labeler logo visible. It highlights a two-step clicking mechanism: the first click with a corresponding color change in the window, a wait time of up to 10 seconds, then the second click with a further color change.*
FDA Label Image

Image (Avt02 Pld Q 17)

Image (Avt02 Pld Q 17)
Illustration showing the use of Adalimumab-ryvk 0.7 mL subcutaneous injection kit. The top image depicts a hand holding a prefilled syringe or pen with an arrow indicating upward motion. The bottom image shows a hand pinching skin, likely demonstrating preparation of the injection site prior to administration.*
FDA Label Image

Figmifuai (Avt02 Pld Q 18)

Figmifuai (Avt02 Pld Q 18)
An instructional illustration showing a human hand disposing of an Adalimumab-ryvk prefilled syringe into a red biohazard sharps container. The syringe is white with an orange needle cover being inserted into the container's yellow-lidded circular opening, demonstrating proper syringe disposal.*
FDA Label Image

Fignifuai (Avt02 Pld Q 19)

FDA Label Image

Figcalifuai (Avt02 Pld Q 20)

Figcalifuai (Avt02 Pld Q 20)
Packaging label for Adalimumab-ryvk Injection 40 mg/0.4 mL kit by Quallent Pharmaceuticals Health LLC. The label indicates the product is for subcutaneous use only and contains 2 single-dose autoinjectors. The label also features a color image of the autoinjector and includes branding and regulatory information.*
FDA Label Image

Avt02-quallent-pfs Image (Avt02 Pld Q 21)

Avt02-quallent-pfs Image (Avt02 Pld Q 21)
An instructional diagram of a syringe illustrating labeled parts including the needle cover, syringe body, finger grip, and plunger. The image highlights the components of a subcutaneous injection syringe typically used for drug administration.*
FDA Label Image

Avt02 Pfs Image Figure A (Avt02 Pld Q 22)

Avt02 Pfs Image Figure A (Avt02 Pld Q 22)
An instructional diagram depicting a hand inserting or retrieving a rectangular object, likely a card or document, into or from a slot within a vertical metallic structure, possibly a machine or device. The illustration uses arrows to indicate the direction of movement.*
FDA Label Image

Figb (Avt02 Pld Q 23)

Figb (Avt02 Pld Q 23)
Illustration of a clock face indicating a time range of 15 to 30 minutes. The right half of the clock is shaded red, emphasizing this time interval. The label "Figure B" is shown below the clock image.*
FDA Label Image

Figc (Avt02 Pld Q 24)

Figc (Avt02 Pld Q 24)
An illustration showing a hand holding a syringe with a clear barrel, highlighting the expiration date printed on the syringe as YYYY/MM/DD. An arrow points from an eye looking closely to the syringe barrel, indicating the need to visually check the expiration date before use.*
FDA Label Image

Figd (Avt02 Pld Q 25)

Figd (Avt02 Pld Q 25)
Illustration showing components of a subcutaneous injection kit, including an alcohol swab package, a cotton ball, and a red sharps disposal container with a yellow lid.*
FDA Label Image

Pfs Image Figure E (Avt02 Pld Q 26)

Pfs Image Figure E (Avt02 Pld Q 26)
An instructional illustration showing hands being washed under a running faucet with water. The image emphasizes hand hygiene, likely related to proper technique or pre-use preparation for medication administration.*
FDA Label Image

Figf (Avt02 Pld Q 27)

Figf (Avt02 Pld Q 27)
An instructional illustration showing recommended injection sites for Adalimumab-ryvk subcutaneous administration. Highlighted areas include the abdomen (around the navel) and the front of the thighs. An inset shows a hand cleaning the injection site with a circular wiping motion, indicating proper site preparation.*
FDA Label Image

Figf (Avt02 Pld Q 28)

Figf (Avt02 Pld Q 28)
An instructional illustration showing hands preparing a syringe by removing a cap from the needle. One hand holds the syringe, and the other hand is pulling off the needle cap upward, indicating a step in medication preparation.*
FDA Label Image

Figh (Avt02 Pld Q 29)

Figh (Avt02 Pld Q 29)
An instructional illustration depicting the subcutaneous injection process using a syringe. The top portion shows a hand holding a syringe with a needle, while the bottom portion shows a hand pinching the skin to administer the injection, consistent with the subcutaneous route for the Adalimumab-ryvk kit.*
FDA Label Image

Figi (Avt02 Pld Q 30)

Figi (Avt02 Pld Q 30)
An instructional illustration showing the proper injection technique for a subcutaneous medication. It depicts a syringe being injected at a 45-degree angle into two possible sites: the abdomen on the left and the thigh on the right.*
FDA Label Image

Figj (Avt02 Pld Q 31)

Figj (Avt02 Pld Q 31)
Illustration showing a hand holding a subcutaneous injection device, positioned at the skin surface for administration. The image highlights the correct angle and grip for injecting a medication, likely part of the Adalimumab-ryvk kit for subcutaneous use.*
FDA Label Image

Figk (Avt02 Pld Q 32)

Figk (Avt02 Pld Q 32)
An illustrated diagram showing a hand holding a syringe with an arrow indicating the direction to inject. The syringe is being positioned for subcutaneous injection into the skin. The illustration demonstrates how to properly administer a subcutaneous injection.*
FDA Label Image

Figl (Avt02 Pld Q 33)

Figl (Avt02 Pld Q 33)
An instructional illustration showing a hand discarding a used syringe into a red sharps disposal container with a yellow lid. The syringe is being safely deposited through the container's oval opening. This image relates to proper disposal of injection equipment.*
FDA Label Image

Figcal (Avt02 Pld Q 34)

Figcal (Avt02 Pld Q 34)
An illustration of a monthly calendar with the word 'MONTH' at the top. The calendar grid contains five rows of circular markers, with white circles in the first four columns and gray circles across the last two columns. The design suggests tracking daily events or dosages within a month.*
FDA Label Image

Image (Avt02 Pld Q 35)

Image (Avt02 Pld Q 35)
Instructional quick guide for Adalimumab-ryvk Injection 40 mg/0.4 mL single-dose autoinjector. The five-step illustrated process shows choosing and cleaning the injection site on thighs or abdomen, removing the needle cap, positioning the autoinjector at a 90-degree angle, administering the injection with audible clicks signaling start and completion, and holding the autoinjector down up to 10 seconds until the viewing window turns all orange.*
FDA Label Image

Image (Avt02 Pld Q 36)

Image (Avt02 Pld Q 36)
Packaging label for Adalimumab-ryvk Injection 40 mg/0.4 mL kit, for subcutaneous use only. The label shows two single-dose autoinjectors and includes the Quallent Pharmaceuticals logo. The label also features product details, dosage form, quantity, and a braille text panel for accessibility.*
FDA Label Image

Pdpsd (Avt02 Pld Q 37)

Pdpsd (Avt02 Pld Q 37)
Packaging label for Adalimumab-ryvk Injection kit, 40 mg/0.4 mL, for subcutaneous use only. The kit contains 2 single-dose prefilled syringes. The label includes usage instructions, manufacturer information (Quallent Pharmaceuticals Health LLC), and storage guidelines. The label also shows an image of a prefilled syringe and includes multiple barcodes and detailed contents of the carton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.